Drugs & Therapy Perspectives

, Volume 28, Issue 11, pp 19–22 | Cite as

The treatment of rheumatoid arthritis in pregnant women requires careful strategies before, during and after pregnancy

Drug Reactions and Interactions
First Online:
  • 68 Downloads
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs 2011; 71 (15): 1973–87PubMedCrossRefGoogle Scholar
  2. 2.
    Amin S, Peterson EJ, Reed AM, et al. Pregnancy and rheumatoid arthritis: insights into the immunology of fetal tolerance and control of autoimmunity. Curr Rheumatol Rep 2011; 13 (5): 449–55PubMedCrossRefGoogle Scholar
  3. 3.
    Nelson JL, Ostensen M. Pregnancy and rheumatoid arthritis. Rheum Dis Clin North Am 1997; 23 (1): 195–212PubMedCrossRefGoogle Scholar
  4. 4.
    Hazes JM, Coulie PG, Geenen V, et al. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford) 2011; 50 (11): 1955–68CrossRefGoogle Scholar
  5. 5.
    FDA pregnancy categories [online]. Available from: URL: http://depts.washington.edu/druginfo/Formulary/Pregnancy.pdf [Accessed 2012 Mar 2]
  6. 6.
    Viktil K, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheumatol 2012; 41 (3): 196–201PubMedCrossRefGoogle Scholar
  7. 7.
    British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 63. London: BMJ Publishing Group Ltd and RPS Publishing, 2012 MarGoogle Scholar
  8. 8.
    European Medicines Agency. Human medicines: product information [online]. Available from URL: http://www.ema.europa.eu [Accessed 2012 Mar 16]
  9. 9.
    Cyclosporine pregnancy and breastfeeding warnings [online]. Available from: URL: http://www.drugs.com/pregnancy/cyclosporine.html [Accessed 2012 Mar 9]
  10. 10.
    Jansen G, van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004; 50 (7): 2130–9PubMedCrossRefGoogle Scholar
  11. 11.
    O’Morain C, Smethurst P, Dore CJ, et al. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984; 25 (10): 1078–84PubMedCrossRefGoogle Scholar
  12. 12.
    Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001; 63 (2): 106–12PubMedCrossRefGoogle Scholar
  13. 13.
    Lloyd ME, Carr M, McElhatton P, et al. The effects of methotrexate on pregnancy, fertility and lactation. QJM 1999; 92 (10): 551–63PubMedCrossRefGoogle Scholar
  14. 14.
    Buckley LM, Bullaboy CA, Leichtman L, et al. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 1997; 40 (5): 971–3PubMedCrossRefGoogle Scholar
  15. 15.
    Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol 1980; 116 (2): 215–7PubMedCrossRefGoogle Scholar
  16. 16.
    Hinkes E, Plotkin D. Reversible drug-induced sterility in a patient with acute leukemia. JAMA 1973; 223 (13): 1490–1PubMedCrossRefGoogle Scholar
  17. 17.
    Carmichael SL, Shaw GM, Ma C, et al. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197 (6): 585, e1–7; discussion 683-4, e1–7PubMedCrossRefGoogle Scholar
  18. 18.
    Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62 (6): 385–92PubMedCrossRefGoogle Scholar
  19. 19.
    Ost L, Wettrell G, Bjorkhem I, et al. Prednisolone excretion in human milk. J Pediatr 1985; 106 (6): 1008–11PubMedCrossRefGoogle Scholar
  20. 20.
    Momma K, Takeuchi H. Constriction of fetal ductus arteriosus by non-steroidal anti-inflammatory drugs. Prostaglandins 1983; 26 (4): 631–43PubMedGoogle Scholar
  21. 21.
    Paladini D, Marasini M, Volpe P. Severe ductal constriction in the third-trimester fetus following maternal self-medication with nime-sulide. Ultrasound Obstet Gynecol 2005; 25 (4): 357–61PubMedCrossRefGoogle Scholar
  22. 22.
    Pham T, Claudepierre P, Constantin A, et al. Abatacept therapy and safety management. Joint Bone Spine 2009; 76 Suppl. 1: S3–55PubMedCrossRefGoogle Scholar
  23. 23.
    Villiger PM, Caliezi G, Cottin V, et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 2010; 69 (10): 1842–4PubMedCrossRefGoogle Scholar
  24. 24.
    Østensen M. Are TNF inhibitors safe in pregnancy? Nat Rev Rheumatol 2009; 5 (4): 184–5PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Personalised recommendations